gabexate has been researched along with Pancreatitis in 139 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Pancreatitis: INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "No significant difference in the occurrence of pancreatitis, hyperamylasemia, or abdominal pain was observed among placebo-, gabexate-, and somatostatin-treated patients." | 10.20 | Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. ( Andriulli, A; Clemente, R; De Maio, G; Leandro, G; Leo, P; Perri, F; Sigillito, A; Solmi, L; Suriani, R; Terruzzi, V, 2002) |
| "The objective of this study is to evaluate the efficacy of somatostatin, ulinastatin and gabexate for the treatment of severe acute pancreatitis." | 9.22 | Effect of Somatostatin, Ulinastatin and Gabexate on the Treatment of Severe Acute Pancreatitis. ( Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF, 2016) |
| "The evidence provided by syntheses of the preventative effects of gabexate mesilate against pancreatitis among patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) is limited and highly heterogeneous." | 9.12 | Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized clinical trials. ( Chang, CC; Chao, CC; Chen, SC; Chiu, YJ; Hou, SK; Kang, YN, 2021) |
| "The objective of the present study was to determine the efficacy of prophylactic administration of gabexate for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, hyperamylasemia and pancreatic pain." | 9.12 | Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Ge, ZZ; Wu, SM; Xiong, GS; Zhang, XW, 2006) |
| "It has been reported that the administration of ulinastatin, gabexate mesylate, or somatostatin may be effective in the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis." | 9.12 | Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial. ( Fujimura, N; Kawamoto, K; Matsui, T; Otani, K; Sakaguchi, S; Shimizu, A; Ueki, T, 2007) |
| "Gabexate mesylate reduces the incidence of post-ERCP pancreatitis." | 9.12 | Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. ( Ardizzone, S; Lombardi, G; Manes, G; Pieramico, O; Porro, GB; Uomo, G, 2007) |
| "It still is debated whether post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis can be prevented by administering either somatostatin or gabexate mesylate." | 9.11 | Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. ( Andriulli, A; Belmonte, A; Ciliberto, E; Festa, V; Forte, G; Leo, P; Loperfido, S; Magnolia, MR; Marenco, G; Monica, F; Perri, F; Sabatino, A; Silla, M; Solmi, L; Spirito, F; Terruzzi, V, 2004) |
| "A continuous 13-h infusion of gabexate starting 30-90 min before endoscopic cholangiopancreatography (ERCP) can reduce postprocedural pancreatitis, the onset of which is generally observed within the first 6 h after ERCP." | 9.10 | Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. ( Cavallini, G; Costamagna, G; Curioni, S; Dragonetti, C; Frulloni, L; Innocenti, P; Macarri, G; Mariani, A; Masci, E; Testoni, PA; Tittobello, A; Uomo, G; Zambelli, S, 2003) |
| "The authors report the results of a randomized, double-blind multicenter clinical trial on the use of gabexate mesilate vs aprotinin in the therapy of acute pancreatitis." | 9.07 | Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.). A prospective, randomized, double-blind multicenter study. ( Bassi, C; Cavallini, G; Falconi, M; Pederzoli, P, 1993) |
| "A multicenter controlled study was performed to evaluate the effect of high doses of the low molecular weight protease inhibitor gabexate mesilate on mortality and complications associated with moderate and severe acute pancreatitis." | 9.07 | Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. ( Adler, G; Beger, HG; Büchler, M; Gaus, W; Malfertheiner, P; Rolle, K; Schölmerich, J; Stöckmann, F; Uhl, W, 1993) |
| "A multicenter, randomized, double-blind trial was carried out to evaluate the efficacy of gabexate mesylate (FOY) in acute pancreatitis." | 9.07 | Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. ( Adrián, MJ; Estruch, J; Navarro, S; Pérez-Mateo, M; Sanjosé, L; Valderrama, R; Vázquez, N, 1992) |
| "We investigated the effect of a new synthetic protease- and phospholipase A2-inhibitor gabexate mesilate (FOY) in a multicenter (6 hospitals in Hannover and vicinity) double-blind study on the clinical course of acute pancreatitis." | 9.06 | [Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients]. ( Freise, J; Horbach, L; Melzer, P; Schmidt, FW, 1986) |
| "We employed the method recommended by the Cochrane Collaboration to perform a meta-analysis of randomized controlled trials (RCTs) of gabexate in the prevention of post-ERCP pancreatitis (PEP) including three RCTs conducted in Italy and one in China." | 8.84 | Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. ( Chen, Y; Li, J; Yang, X; Zeng, Q; Zhang, Y; Zheng, M, 2007) |
| "Our purpose was to update the meta-analysis on somatostatin (SS, 16 studies) or gabexate mesylate (GM, 9 studies) prophylaxis of post-ERCP pancreatitis and to run sensitivity analyses by subgrouping trials according to schedules of drug administration." | 8.84 | Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. ( Andriulli, A; Annese, V; Federici, T; Forlano, R; Iacobellis, A; Ippolito, A; Leandro, G, 2007) |
| "Prior studies have suggested the efficacy of somatostatin and gabexate in post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis prevention." | 8.84 | Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. ( Kiss, A; Rudin, D; Sottile, VM; Wetz, RV, 2007) |
| "Since the effectiveness of gabexate mesilate in patients with acute pancreatitis is controversial, a metaanalysis of the published literature was conducted to address this problem." | 8.79 | Effectiveness of gabexate mesilate in acute pancreatitis. A metaanalysis. ( Bassi, C; Falconi, M; Martini, N; Messori, A; Olivato, R; Pederzoli, P; Rampazzo, R; Scroccaro, G, 1995) |
| "We have previously shown that gabexate mesylate-poloxamer 407 conjugate (GMTI) alleviates traumatic pancreatitis in rats." | 8.31 | Gabexate Mesylate-Poloxamer 407 Conjugate Alleviates Sodium Taurocholate-Induced Severe Acute Pancreatitis in an Optimized Rat Model. ( Gao, H; Gao, Y; Jiao, Z; Luo, Y; Song, Q; Wu, W; Yang, J, 2023) |
| " The prophylaxis for acute pancreatitis (AP) post-endoscopic retrograde cholangiopancreatography (ERCP) consists of rectal indomethacin, but some studies are not concordant." | 7.85 | Rectal indomethacin or intravenous gabexate mesylate as prophylaxis for acute pancreatitis post-endoscopic retrograde cholangiopancreatography. ( Giorgio, P; Guerra, V; Guglielmi, V; Tutino, M, 2017) |
| "Gabexate mesilate (GM) is a trypsin inhibitor, and mainly used for treatment of various acute pancreatitis, including traumatic pancreatitis (TP), edematous pancreatitis, and acute necrotizing pancreatitis." | 7.81 | A novel thermosensitive in-situ gel of gabexate mesilate for treatment of traumatic pancreatitis: An experimental study. ( Gao, HJ; Luo, YK; Lv, FQ; Mei, XG; Song, Q; Tang, J; Wang, S; Wang, YR, 2015) |
| "Ciprofloxacin is considered to be a safe and effective treatment for acute infectious colitis." | 7.80 | Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis. ( Cheung, DY; Cho, HJ; Cho, SH; Kim, JI; Kim, JK; Kim, SS; Lee, HJ; Sung, HY, 2014) |
| "The present study showed that gabexate infusion has some clinical benefits for acute pancreatitis in children." | 7.79 | Clinical efficacy of gabexate mesilate for acute pancreatitis in children. ( Kim, SC; Yang, HR, 2013) |
| "Despite a lack of evidence, gabexate mesylate (GM) is routinely used for the treatment of acute pancreatitis (AP) in some countries." | 7.79 | Effect and cost of treatment for acute pancreatitis with or without gabexate mesylate: a propensity score analysis using a nationwide administrative database. ( Fushimi, K; Hashimoto, H; Horiguchi, H; Matsuda, S; Yasunaga, H, 2013) |
| "To evaluate the efficacy of continuous regional arterial infusion therapy (CRAI) with gabexate mesilate and antibiotics for severe acute pancreatitis (SAP)." | 7.74 | Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis. ( Akashi, T; Arita, Y; Furukawa, M; Igarashi, H; Ino, Y; Ito, T; Kawabe, K; Kimura, T; Miyahara, T; Ogoshi, K; Oono, T; Ouchi, J; Takayanagi, R, 2008) |
| "Camostat mesilate (CM), an oral protease inhibitor, has been used clinically for the treatment of chronic pancreatitis in Japan." | 7.73 | Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. ( Arita, Y; Fujimori, N; Gibo, J; Hisano, T; Inoue, M; Ito, T; Kawabe, K; Nawata, H; Oono, T, 2005) |
| "Gabexate mesylate is a drug marketed only in Italy and Japan and it is considered an essential drug in the treatment of acute pancreatitis." | 7.73 | Gabexate mesilate and acute pancreatitis: an experience of evidence based drug information for improving rational drug use. ( Aiazzi, M; Banfi, R; Borselli, G; Cappelletti, S; Mari, L; Taddei, V, 2005) |
| "Routine gabexate prophylaxis was associated with a significant reduction of post-ERCP pancreatitis rate, severe hyperamylasaemia and hospitalisation-related costs only in high-risk patients." | 7.73 | Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis. ( Curioni, S; Mariani, A; Masci, E; Testoni, PA, 2006) |
| "An oral protease inhibitor, camostat mesilate (CM) has been used clinically for chronic pancreatitis (CP) in Japan, but it lacks enough scientific evidence of its effectiveness." | 7.71 | Effect of camostat mesilate on the expression of pancreatitis-associated protein (PAP), p8, and cytokines in rat spontaneous chronic pancreatitis. ( Iovanna, JL; Motoo, Y; Sawabu, N; Su, SB; Xie, MJ, 2001) |
| " In this report, the effects of loxiglumide and gabexate mesilate were studied on three experimental acute pancreatitis models induced by caerulein, sodium taurocholate + caerulein and closed duodenal loop." | 7.70 | Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate. ( Fujii, M; Kasai, H; Kimura, K; Saito, T; Tominaga, K, 1998) |
| "An experimental model of chronic pancreatitis was induced by a retrograde injection of a viscous solution consisting of zein-oleic acid-linoleic acid (0." | 7.70 | Pathophysiologic studies of experimental chronic pancreatitis in rats induced by injection of zein-oleic acid-linoleic acid solution into the pancreatic duct. ( Kashima, K; Kataoka, K; Sakagami, J; Sasaki, T; Yorizumi, H, 1998) |
| "This study was undertaken to determine whether synthetic proteinase inhibitors--nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) have any influence on multiorgan oxidant-antioxidant balance in acute haemorrhagic pancreatitis induced in Wistar rats using a retrograde intraductal injection of 5% Na-taurocholate." | 7.69 | The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis. ( Dabrowski, A; Gabryelewicz, A, 1994) |
| "The present study investigates the effect of oral pretreatment with the protease inhibitor camostate on the outcome of pancreatitis in three experimental models." | 7.68 | Effect of camostate administration for two weeks on experimental pancreatitis in mice and rats. ( Creutzfeldt, W; Leonhardt, U; Seidensticker, F; Stöckmann, F, 1993) |
| "Systemic prostacyclin and thromboxane A2 production in rat experimental acute pancreatitis has been evaluated by measuring the urinary excretion of the 2,3-dinor 6-keto prostaglandin F1 alpha and 2,3-dinor thromboxane B2, respectively." | 7.68 | Changes of systemic prostacyclin and thromboxane A2 in sodium taurocholate- and cerulein-induced acute pancreatitis in rats. ( Bulbena, O; Closa, D; Fernandez-Cruz, L; Gelpi, E; Hotter, G; Martrat, A; Rosello-Catafau, J, 1993) |
| "In vivo microscopy was performed to assess the effect of dextran 40, gabexate mesilate and somatostatin on the microcirculation in sodium taurocholate-induced pancreatitis in rats." | 7.68 | The effect of somatostatin, gabexate mesilate and dextran 40 on the microcirculation in sodium taurocholate-induced pancreatitis. ( Enghofer, M; Kusterer, K; Poschmann, T; Usadel, KH, 1992) |
| "The therapeutic effect and the mechanism of action of the synthetic trypsin inhibitor camostate were studied in a rat model of acute interstitial pancreatitis induced by four subcutaneous injections of 20 micrograms/kg body weight of cerulein at hourly intervals." | 7.68 | Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats. ( Fuji, M; Fujisawa, T; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990) |
| "Due to its biochemical properties, the newly developed low-molecular protease inhibitor gabexate mesilate is assumed to be efficient in the treatment of complicated acute pancreatitis." | 7.68 | [The protease inhibitor gabexate mesilate in experimentally-induced acute pancreatitis with early gram-negative infection in the Göttingen minipig: therapeutic efficacy and effects on blood coagulation and fibrinolysis]. ( Emde, C; Heitz, J; Jansen, U; Schäfer, JH; Semsch, B, 1990) |
| "The effect of peritoneal lavage with the addition of camostate to the lavage fluid on the outcome of taurocholate pancreatitis in rats was studied." | 7.68 | Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis. ( Creutzfeldt, W; Fussek, M; Leonhardt, U; Seidensticker, F; Stöckmann, F, 1990) |
| "The effects of the cholecystokinin (CCK)-receptor antagonist proglumide, the protease inhibitor gabexate, and the hormones secretin and cholecystokinin-octapeptide (CCK-8) were studied in a model of acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented (CDE) diet." | 7.67 | Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. ( Ferrell, LD; Grendell, JH; Liddle, RA; Niederau, C, 1986) |
| "The effects of gabexate mesilate (GM) on hemodynamics and phospholipase A2 activities (PLA2) during acute hemorrhagic pancreatitis (AHP) were studied in 17 piglets which were randomly divided into three groups: The control group (CG) received only the fluid replacement, whereas the pretreatment group (PG) was given an infusion of GM (20 mg/kg/5h), which was started 30 min before and in the treatment group (TG) 30 min after the induction of AHP." | 7.67 | The effect of gabexate mesilate on the outcome of acute hemorrhagic pancreatitis in pigs. ( Gröhn, P; Kiviniemi, H; Mahlberg, K; Mokka, RE; Rämö, OJ; Ristkari, SK, 1989) |
| "Two models of severe acute pancreatitis were chosen and pancreatitis induced by sodium taurocholate and by a choline-deficient ethionine-supplemented diet, to evaluate the effectiveness of FOY-305 (camostate), a new synthetic trypsin inhibitor." | 7.67 | Effect of FOY-305 (camostate) on severe acute pancreatitis in two experimental animal models. ( Göke, B; Gröne, HJ; Lankisch, PG; Otto, J; Pohl, U; Rahlf, G; Wereszczynska-Siemiatkowska, U, 1989) |
| "In order to evaluate the efficacy and safety of gabexate mesilate (FOY = [ethyl-4-(6-guanidinohexanoyloxy) benzoate methane sulfonate]), a synthetic inhibitor of various proteases as well as phospholipase A 2, 17 patients with acute pancreatitis were treated with FOY in doses of 3 X 150 mg/day per i." | 7.66 | [Therapy of acute pancreatitis with a synthetic protease and phospholipase A2 inhibitor gabexate mesilate]. ( Freise, J, 1983) |
| "No significant difference in the occurrence of pancreatitis, hyperamylasemia, or abdominal pain was observed among placebo-, gabexate-, and somatostatin-treated patients." | 6.20 | Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. ( Andriulli, A; Clemente, R; De Maio, G; Leandro, G; Leo, P; Perri, F; Sigillito, A; Solmi, L; Suriani, R; Terruzzi, V, 2002) |
| "Gabexate mesilate was infused intravenously 6 hours after the initiation of induction of acute pancreatitis at doses of 0." | 5.30 | Gabexate mesilate improves pancreatic microcirculation and reduces lung edema in a rat model of acute pancreatitis. ( Chen, HM; Chen, MF; Shyr, MH, 1997) |
| "Antiprotease has long been used for the treatment of acute pancreatitis, although its effects and mechanism have not been fully elucidated." | 5.29 | The effect of gabexate mesilate on pancreatic and hepatic microcirculation in acute experimental pancreatitis in rats. ( Chen, HM; Chen, MF; Hwang, TL, 1996) |
| "Acute pancreatitis was induced in ten anesthetized dogs by retrograde injection for bile mixed with trypsin into the pancreatic duct." | 5.28 | Effect on hemodynamics of therapeutic infusion of gabexate mesilate (FOY) in experimental acute pancreatitis. ( Babicki, A; Basiński, A; Dobosz, M; Sledziński, Z; Stanek, A; Wajda, Z, 1989) |
| "Comparing the two groups of acute pancreatitis patients after 6 days of treatment with gabexate mesilate, we observed a statistically significantly lower alpha-amylase activity in the serum of treated patients compared with the placebo group." | 5.27 | Gabexate mesilate and camostate: new inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis. ( Freise, J; Magerstedt, P; Schmid, K; Schmidt, FW, 1985) |
| "The objective of this study is to evaluate the efficacy of somatostatin, ulinastatin and gabexate for the treatment of severe acute pancreatitis." | 5.22 | Effect of Somatostatin, Ulinastatin and Gabexate on the Treatment of Severe Acute Pancreatitis. ( Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF, 2016) |
| "The evidence provided by syntheses of the preventative effects of gabexate mesilate against pancreatitis among patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) is limited and highly heterogeneous." | 5.12 | Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized clinical trials. ( Chang, CC; Chao, CC; Chen, SC; Chiu, YJ; Hou, SK; Kang, YN, 2021) |
| "The objective of the present study was to determine the efficacy of prophylactic administration of gabexate for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, hyperamylasemia and pancreatic pain." | 5.12 | Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Ge, ZZ; Wu, SM; Xiong, GS; Zhang, XW, 2006) |
| "It has been reported that the administration of ulinastatin, gabexate mesylate, or somatostatin may be effective in the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis." | 5.12 | Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial. ( Fujimura, N; Kawamoto, K; Matsui, T; Otani, K; Sakaguchi, S; Shimizu, A; Ueki, T, 2007) |
| "Gabexate mesylate reduces the incidence of post-ERCP pancreatitis." | 5.12 | Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. ( Ardizzone, S; Lombardi, G; Manes, G; Pieramico, O; Porro, GB; Uomo, G, 2007) |
| "It still is debated whether post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis can be prevented by administering either somatostatin or gabexate mesylate." | 5.11 | Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. ( Andriulli, A; Belmonte, A; Ciliberto, E; Festa, V; Forte, G; Leo, P; Loperfido, S; Magnolia, MR; Marenco, G; Monica, F; Perri, F; Sabatino, A; Silla, M; Solmi, L; Spirito, F; Terruzzi, V, 2004) |
| "A continuous 13-h infusion of gabexate starting 30-90 min before endoscopic cholangiopancreatography (ERCP) can reduce postprocedural pancreatitis, the onset of which is generally observed within the first 6 h after ERCP." | 5.10 | Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. ( Cavallini, G; Costamagna, G; Curioni, S; Dragonetti, C; Frulloni, L; Innocenti, P; Macarri, G; Mariani, A; Masci, E; Testoni, PA; Tittobello, A; Uomo, G; Zambelli, S, 2003) |
| "Prophylactic treatment with gabexate reduced pancreatic damage related to ERCP, as reflected by reductions in the extent but not the frequency of elevated enzyme levels and in the frequency of pancreatic pain and acute pancreatitis." | 5.08 | Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group. ( Cavallini, G; Di Francesco, V; Frulloni, L; Mariana, A; Masci, E; Tittobello, A, 1996) |
| "The authors report the results of a randomized, double-blind multicenter clinical trial on the use of gabexate mesilate vs aprotinin in the therapy of acute pancreatitis." | 5.07 | Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.). A prospective, randomized, double-blind multicenter study. ( Bassi, C; Cavallini, G; Falconi, M; Pederzoli, P, 1993) |
| "A multicenter controlled study was performed to evaluate the effect of high doses of the low molecular weight protease inhibitor gabexate mesilate on mortality and complications associated with moderate and severe acute pancreatitis." | 5.07 | Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. ( Adler, G; Beger, HG; Büchler, M; Gaus, W; Malfertheiner, P; Rolle, K; Schölmerich, J; Stöckmann, F; Uhl, W, 1993) |
| "A multicenter, randomized, double-blind trial was carried out to evaluate the efficacy of gabexate mesylate (FOY) in acute pancreatitis." | 5.07 | Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. ( Adrián, MJ; Estruch, J; Navarro, S; Pérez-Mateo, M; Sanjosé, L; Valderrama, R; Vázquez, N, 1992) |
| "We investigated the effect of a new synthetic protease- and phospholipase A2-inhibitor gabexate mesilate (FOY) in a multicenter (6 hospitals in Hannover and vicinity) double-blind study on the clinical course of acute pancreatitis." | 5.06 | [Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients]. ( Freise, J; Horbach, L; Melzer, P; Schmidt, FW, 1986) |
| "We employed the method recommended by the Cochrane Collaboration to perform a meta-analysis of randomized controlled trials (RCTs) of gabexate in the prevention of post-ERCP pancreatitis (PEP) including three RCTs conducted in Italy and one in China." | 4.84 | Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. ( Chen, Y; Li, J; Yang, X; Zeng, Q; Zhang, Y; Zheng, M, 2007) |
| "Our purpose was to update the meta-analysis on somatostatin (SS, 16 studies) or gabexate mesylate (GM, 9 studies) prophylaxis of post-ERCP pancreatitis and to run sensitivity analyses by subgrouping trials according to schedules of drug administration." | 4.84 | Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. ( Andriulli, A; Annese, V; Federici, T; Forlano, R; Iacobellis, A; Ippolito, A; Leandro, G, 2007) |
| "Prior studies have suggested the efficacy of somatostatin and gabexate in post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis prevention." | 4.84 | Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. ( Kiss, A; Rudin, D; Sottile, VM; Wetz, RV, 2007) |
| "The study described the pattern of use of gabexate mesylate in Italian hospitals and provided information on the outcome of the subgroup treated for acute pancreatitis." | 4.82 | Use of gabexate mesylate in Italian hospitals: a multicentre observational study. ( Cecchi, M; Messori, A; Pelagotti, F, 2003) |
| "Since the effectiveness of gabexate mesilate in patients with acute pancreatitis is controversial, a metaanalysis of the published literature was conducted to address this problem." | 4.79 | Effectiveness of gabexate mesilate in acute pancreatitis. A metaanalysis. ( Bassi, C; Falconi, M; Martini, N; Messori, A; Olivato, R; Pederzoli, P; Rampazzo, R; Scroccaro, G, 1995) |
| "We have previously shown that gabexate mesylate-poloxamer 407 conjugate (GMTI) alleviates traumatic pancreatitis in rats." | 4.31 | Gabexate Mesylate-Poloxamer 407 Conjugate Alleviates Sodium Taurocholate-Induced Severe Acute Pancreatitis in an Optimized Rat Model. ( Gao, H; Gao, Y; Jiao, Z; Luo, Y; Song, Q; Wu, W; Yang, J, 2023) |
| " The prophylaxis for acute pancreatitis (AP) post-endoscopic retrograde cholangiopancreatography (ERCP) consists of rectal indomethacin, but some studies are not concordant." | 3.85 | Rectal indomethacin or intravenous gabexate mesylate as prophylaxis for acute pancreatitis post-endoscopic retrograde cholangiopancreatography. ( Giorgio, P; Guerra, V; Guglielmi, V; Tutino, M, 2017) |
| "Gabexate mesilate (GM) is a trypsin inhibitor, and mainly used for treatment of various acute pancreatitis, including traumatic pancreatitis (TP), edematous pancreatitis, and acute necrotizing pancreatitis." | 3.81 | A novel thermosensitive in-situ gel of gabexate mesilate for treatment of traumatic pancreatitis: An experimental study. ( Gao, HJ; Luo, YK; Lv, FQ; Mei, XG; Song, Q; Tang, J; Wang, S; Wang, YR, 2015) |
| "Ciprofloxacin is considered to be a safe and effective treatment for acute infectious colitis." | 3.80 | Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis. ( Cheung, DY; Cho, HJ; Cho, SH; Kim, JI; Kim, JK; Kim, SS; Lee, HJ; Sung, HY, 2014) |
| "The present study showed that gabexate infusion has some clinical benefits for acute pancreatitis in children." | 3.79 | Clinical efficacy of gabexate mesilate for acute pancreatitis in children. ( Kim, SC; Yang, HR, 2013) |
| "Despite a lack of evidence, gabexate mesylate (GM) is routinely used for the treatment of acute pancreatitis (AP) in some countries." | 3.79 | Effect and cost of treatment for acute pancreatitis with or without gabexate mesylate: a propensity score analysis using a nationwide administrative database. ( Fushimi, K; Hashimoto, H; Horiguchi, H; Matsuda, S; Yasunaga, H, 2013) |
| "To evaluate the efficacy of continuous regional arterial infusion therapy (CRAI) with gabexate mesilate and antibiotics for severe acute pancreatitis (SAP)." | 3.74 | Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis. ( Akashi, T; Arita, Y; Furukawa, M; Igarashi, H; Ino, Y; Ito, T; Kawabe, K; Kimura, T; Miyahara, T; Ogoshi, K; Oono, T; Ouchi, J; Takayanagi, R, 2008) |
| "Camostat mesilate, an orally available proteinase inhibitor, is clinically used for treatment of pancreatitis." | 3.74 | The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents. ( Ishiki, T; Ishikura, H; Kamanaka, Y; Kawabata, A; Matsunami, M; Nakatani, T; Naruse, M; Nishimura, S; Sekiguchi, F; Tsujiuchi, T, 2007) |
| "Camostat mesilate (CM), an oral protease inhibitor, has been used clinically for the treatment of chronic pancreatitis in Japan." | 3.73 | Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. ( Arita, Y; Fujimori, N; Gibo, J; Hisano, T; Inoue, M; Ito, T; Kawabe, K; Nawata, H; Oono, T, 2005) |
| "Gabexate mesylate is a drug marketed only in Italy and Japan and it is considered an essential drug in the treatment of acute pancreatitis." | 3.73 | Gabexate mesilate and acute pancreatitis: an experience of evidence based drug information for improving rational drug use. ( Aiazzi, M; Banfi, R; Borselli, G; Cappelletti, S; Mari, L; Taddei, V, 2005) |
| "Routine gabexate prophylaxis was associated with a significant reduction of post-ERCP pancreatitis rate, severe hyperamylasaemia and hospitalisation-related costs only in high-risk patients." | 3.73 | Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis. ( Curioni, S; Mariani, A; Masci, E; Testoni, PA, 2006) |
| "An oral protease inhibitor, camostat mesilate (CM) has been used clinically for chronic pancreatitis (CP) in Japan, but it lacks enough scientific evidence of its effectiveness." | 3.71 | Effect of camostat mesilate on the expression of pancreatitis-associated protein (PAP), p8, and cytokines in rat spontaneous chronic pancreatitis. ( Iovanna, JL; Motoo, Y; Sawabu, N; Su, SB; Xie, MJ, 2001) |
| "Gabexate mesilate is an antiprotease drug, which reduced the severity of pancreatitis and frequency of post-ERCP pancreatitis." | 3.71 | Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility. ( Angelini, G; Cavallini, G; Di Francesco, V; Frulloni, L; Mariani, A; Masci, E; Passaretti, S; Talamini, G; Testoni, P, 2002) |
| " In this report, the effects of loxiglumide and gabexate mesilate were studied on three experimental acute pancreatitis models induced by caerulein, sodium taurocholate + caerulein and closed duodenal loop." | 3.70 | Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate. ( Fujii, M; Kasai, H; Kimura, K; Saito, T; Tominaga, K, 1998) |
| "An experimental model of chronic pancreatitis was induced by a retrograde injection of a viscous solution consisting of zein-oleic acid-linoleic acid (0." | 3.70 | Pathophysiologic studies of experimental chronic pancreatitis in rats induced by injection of zein-oleic acid-linoleic acid solution into the pancreatic duct. ( Kashima, K; Kataoka, K; Sakagami, J; Sasaki, T; Yorizumi, H, 1998) |
| "The effect of methylcarbonylmethyl 2(S)-14-(4-guanidino-benzoyloxy) phenyl] propionate methanesulfonate (TT-S24) on experimental pancreatitis in rats was examined in comparison with that of camostat." | 3.70 | Effect of methylcarbonylmethyl 2(S)-[4-(4-guanidino-benzoyloxy)phenyl] propionate methanesulfonate (TT-S24) on experimental pancreatitis in rats. ( Abe, S; Kamei, C; Tagami, H; Tanaka, I; Yoshida, Y, 1998) |
| "This study was undertaken to determine whether synthetic proteinase inhibitors--nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) have any influence on multiorgan oxidant-antioxidant balance in acute haemorrhagic pancreatitis induced in Wistar rats using a retrograde intraductal injection of 5% Na-taurocholate." | 3.69 | The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis. ( Dabrowski, A; Gabryelewicz, A, 1994) |
| "The effect of oral administration of protease inhibitor (camostat) on pancreatic morphology and exocrine function (conscious rat model) was investigated using WBN/Kob rats with spontaneous chronic pancreatitis." | 3.69 | Effect of oral administration of protease inhibitor on pancreatic exocrine function in WBN/Kob rats with chronic pancreatitis. ( Atomi, Y; Kobori, O; Kuroda, A; Muto, T; Sugiyama, M; Wada, N, 1996) |
| "We evaluated the protective effect of the CCK receptor antagonist L-364,718 (devazepide) and of the trypsin inhibitor camostat, on taurocholate-induced pancreatitis in rats." | 3.69 | The cholecystokinin receptor antagonist L-364,718 reduces taurocholate-induced pancreatitis in rats. ( Kim, DG; Kim, KH; Lee, MG, 1996) |
| "Effects of a new cholecystokinin (CCK)A-receptor antagonist, T-0632 [sodium (S)-1-(2-fluorophenyl)-2, 3-dihydro-3-[(3-isoquinolinylcarbonyl) amino]-6-methoxy-2-oxo-1H-indole-3-propanoate], on caerulein-induced and pancreatic duct ligation-induced pancreatitis models were studied and compared with the CCKA-receptor antagonist loxiglumide and the orally active protease inhibitor camostate, respectively." | 3.69 | Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. ( Endo, T; Kume, E; Nagasaki, M; Shikano, T; Taniguchi, H; Yomota, E, 1997) |
| "A 59-year-old Japanese man developed septal panniculitis with eosinophilic infiltration in both forearms and the dorsum of the left hand after a gabexate mesilate intravenous drip infusion for acute pancreatitis through catheters implanted in these sites." | 3.69 | Panniculitis with eosinophilic infiltration due to gabexate mesilate (FOY): possibility of allergic reaction. ( Nakayama, F, 1997) |
| "The present study investigates the effect of oral pretreatment with the protease inhibitor camostate on the outcome of pancreatitis in three experimental models." | 3.68 | Effect of camostate administration for two weeks on experimental pancreatitis in mice and rats. ( Creutzfeldt, W; Leonhardt, U; Seidensticker, F; Stöckmann, F, 1993) |
| "Systemic prostacyclin and thromboxane A2 production in rat experimental acute pancreatitis has been evaluated by measuring the urinary excretion of the 2,3-dinor 6-keto prostaglandin F1 alpha and 2,3-dinor thromboxane B2, respectively." | 3.68 | Changes of systemic prostacyclin and thromboxane A2 in sodium taurocholate- and cerulein-induced acute pancreatitis in rats. ( Bulbena, O; Closa, D; Fernandez-Cruz, L; Gelpi, E; Hotter, G; Martrat, A; Rosello-Catafau, J, 1993) |
| "In vivo microscopy was performed to assess the effect of dextran 40, gabexate mesilate and somatostatin on the microcirculation in sodium taurocholate-induced pancreatitis in rats." | 3.68 | The effect of somatostatin, gabexate mesilate and dextran 40 on the microcirculation in sodium taurocholate-induced pancreatitis. ( Enghofer, M; Kusterer, K; Poschmann, T; Usadel, KH, 1992) |
| "The present study investigated the protective effects of the new potent synthetic protease inhibitors, ONO3307 (4-sulfamoyl phenyl-4-guanidinobenzoate methanesulfonate) and FOY007 (gabexate misilate), on the exocrine pancreas in rat caerulein-induced acute pancreatitis in both in vitro and in vivo experiments." | 3.68 | Protection by a new synthetic protease inhibitor, ONO3307, of the rat exocrine pancreas during acute edematous pancreatitis induced by a supramaximal dose of caerulein in comparison with FOY007. ( Hirano, T; Manabe, T; Tobe, T, 1992) |
| "The therapeutic effect and the mechanism of action of the synthetic trypsin inhibitor camostate were studied in a rat model of acute interstitial pancreatitis induced by four subcutaneous injections of 20 micrograms/kg body weight of cerulein at hourly intervals." | 3.68 | Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats. ( Fuji, M; Fujisawa, T; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990) |
| " Caerulein-induced pancreatitis or treatment with the synthetic protease inhibitor camostate had no significant effects on permeability." | 3.68 | Pancreatic microvascular permeability in caerulein-induced acute pancreatitis. ( Mann, GE; Sweiry, JH, 1991) |
| "Due to its biochemical properties, the newly developed low-molecular protease inhibitor gabexate mesilate is assumed to be efficient in the treatment of complicated acute pancreatitis." | 3.68 | [The protease inhibitor gabexate mesilate in experimentally-induced acute pancreatitis with early gram-negative infection in the Göttingen minipig: therapeutic efficacy and effects on blood coagulation and fibrinolysis]. ( Emde, C; Heitz, J; Jansen, U; Schäfer, JH; Semsch, B, 1990) |
| "The effect of peritoneal lavage with the addition of camostate to the lavage fluid on the outcome of taurocholate pancreatitis in rats was studied." | 3.68 | Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis. ( Creutzfeldt, W; Fussek, M; Leonhardt, U; Seidensticker, F; Stöckmann, F, 1990) |
| "The effects of the cholecystokinin (CCK)-receptor antagonist proglumide, the protease inhibitor gabexate, and the hormones secretin and cholecystokinin-octapeptide (CCK-8) were studied in a model of acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented (CDE) diet." | 3.67 | Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. ( Ferrell, LD; Grendell, JH; Liddle, RA; Niederau, C, 1986) |
| "The effect of a synthetic protease inhibitor, gabexate mesilate (GM), which was administered directly into the pancreatic duct, on acute pancreatitis induced by sodium taurocholate in dogs was investigated." | 3.67 | Prevention of the spread of experimental acute pancreatitis by intraductal administration of a synthetic protease inhibitor in dogs. ( Idezuki, Y; Itoh, T; Shibayama, K; Wakayama, T, 1989) |
| "The effects of gabexate mesilate (GM) on hemodynamics and phospholipase A2 activities (PLA2) during acute hemorrhagic pancreatitis (AHP) were studied in 17 piglets which were randomly divided into three groups: The control group (CG) received only the fluid replacement, whereas the pretreatment group (PG) was given an infusion of GM (20 mg/kg/5h), which was started 30 min before and in the treatment group (TG) 30 min after the induction of AHP." | 3.67 | The effect of gabexate mesilate on the outcome of acute hemorrhagic pancreatitis in pigs. ( Gröhn, P; Kiviniemi, H; Mahlberg, K; Mokka, RE; Rämö, OJ; Ristkari, SK, 1989) |
| "Two models of severe acute pancreatitis were chosen and pancreatitis induced by sodium taurocholate and by a choline-deficient ethionine-supplemented diet, to evaluate the effectiveness of FOY-305 (camostate), a new synthetic trypsin inhibitor." | 3.67 | Effect of FOY-305 (camostate) on severe acute pancreatitis in two experimental animal models. ( Göke, B; Gröne, HJ; Lankisch, PG; Otto, J; Pohl, U; Rahlf, G; Wereszczynska-Siemiatkowska, U, 1989) |
| "In this study we evaluated the effects of hydration, oxygenation, peritoneal lavage, and the protease inhibitor gabexate mesilate in acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented diet." | 3.67 | Therapeutic regimens in acute experimental hemorrhagic pancreatitis. Effects of hydration, oxygenation, peritoneal lavage, and a potent protease inhibitor. ( Crass, RA; Ferrell, LD; Grendell, JH; Niederau, C; Silver, G, 1988) |
| "In mongrel dogs with induced pancreatitis we studied the effects of the nonspecific phospholipase A2-inhibitors chlorpromazine, gabexate mesilate and CaNa2EDTA on the course of pancreatogenic shock and the intrapancreatic lysolecithin production." | 3.67 | [Phospholipase A2 inhibitors in hemorrhagic-necrotizing pancreatitis. Animal experiment evaluation of a new treatment concept]. ( Alles, JU; Kahle, M; Klein, U; König, W; Martin, U, 1985) |
| "In order to evaluate the efficacy and safety of gabexate mesilate (FOY = [ethyl-4-(6-guanidinohexanoyloxy) benzoate methane sulfonate]), a synthetic inhibitor of various proteases as well as phospholipase A 2, 17 patients with acute pancreatitis were treated with FOY in doses of 3 X 150 mg/day per i." | 3.66 | [Therapy of acute pancreatitis with a synthetic protease and phospholipase A2 inhibitor gabexate mesilate]. ( Freise, J, 1983) |
| " These results may justify further, larger scale studies or evaluation of alternate dosage or route of administration." | 2.66 | Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. ( Chang-Chien, CS; Liaw, YF; Yang, CY, 1987) |
| "In about 1% acute pancreatitis or recurrency of chronic pancreatitis occurs." | 2.65 | [Effect of secretin and gabexate-mesilate (synthetic protease inhibitor) on serum amylase level after ERCP]. ( Rösch, W; Tympner, F, 1982) |
| "Acute pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP)." | 2.44 | Early successes and late failures in the prevention of post endoscopic retrograde cholangiopancreatography. ( Draganov, PV; Lieb, JG, 2007) |
| "Nitroglycerin (NGL) is a nitrogen oxide (NO) donor, which relaxes the sphincter of Oddi." | 2.44 | Pharmacological approach to acute pancreatitis. ( Bang, UC; Bendtsen, F; Nojgaard, C; Semb, S, 2008) |
| " Initial studies using ulinastatin are promising but additional dose-response studies are needed." | 2.43 | Pharmacological management of pancreatitis. ( Hoogerwerf, WA, 2005) |
| "The management of acute pancreatitis (AP) is still based on speculative and unproven paradigms in many centers." | 2.43 | Evidence-based treatment of acute pancreatitis: a look at established paradigms. ( Clavien, PA; Heinrich, S; Rousson, V; Schäfer, M, 2006) |
| "Acute pancreatitis is a disease with a wide variety of pathophysiologies, ranging from mild to severe condition." | 2.42 | [Essential therapeutic strategies for acute pancreatitis--guidelines for initial treatment and their significance]. ( Hirata, K, 2004) |
| "Protease inhibitors are used to treat acute pancreatitis, but their effectiveness remains unclear." | 2.42 | Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. ( Fukui, T; Noguchi, Y; Seta, T; Shikata, S; Shimada, T, 2004) |
| "57], p = 0." | 2.41 | Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. ( Andriulli, A; Conoscitore, P; De Maio, G; Facciorusso, D; Festa, V; Gambassi, G; Leandro, G; Mangia, A; Niro, G; Spirito, F; Villani, MR, 2000) |
| "Pancreatitis is rightly the most feared complication of endoscopic retrograde cholangiopancreatography (ERCP)." | 2.41 | Predicting and preventing post-ERCP pancreatitis. ( Baillie, J, 2002) |
| "Today, the mortality in severe acute pancreatitis is determined by septic complications due to infected pancreatic necroses in the late phase 2-3 weeks after the onset of the disease." | 2.39 | Protease-antiprotease interactions and the rationale for therapeutic protease inhibitors. ( Büchler, MW; Schmid, S; Uhl, W, 1996) |
| " During the follow-up CT and dosage amylase and lipase in blood were performed." | 1.40 | [Acute pancreatitis in pediatric age: our experience in 52 cases]. ( Cofini, M; Favoriti, P; Quadrozzi, F, 2014) |
| "The incidence of acute pancreatitis associated with diagnostic and therapeutic ERCP is 0." | 1.36 | Post-ERCP pancreatitis. ( Amano, H; Arata, S; Gabata, T; Hirata, K; Hirota, M; Ito, T; Kataoka, K; Kimura, Y; Kiriyama, S; Mayumi, T; Sekimoto, M; Takada, T; Takeda, K; Tanaka, M; Wada, K; Yokoe, M; Yoshida, M, 2010) |
| "However two cases had mild acute pancreatitis in the group B." | 1.34 | Evaluation of serum amylase and gabexate mesilate with endoscopic papillary balloon dilatation. ( Aoki, R; Ito, S; Muguruma, N; Nakamoto, J; Nakasono, M; Okamura, S; Sato, Y, 2007) |
| "Acute pancreatitis is a pancreatic inflammation that recognises Salmonella typhi among its aetiological agents." | 1.34 | [Typhoid fever and acute pancreatitis: two cases]. ( Bertuccio, SN; Rombolà, F, 2007) |
| "Thus, the main problem in acute pancreatitis, especially in the severe form of the disease, is the difficulty of planning clinical studies capable of giving hard statistically significant answers regarding the benefits of the various proposed therapeutic agents previously tested in experimental settings." | 1.33 | New approaches for the treatment of acute pancreatitis. ( Fantini, L; Morselli-Labate, AM; Pezzilli, R, 2006) |
| "This is the first case report of severe acute pancreatitis in the setting of overlap syndrome of SLE and SSc." | 1.33 | A case of severe acute pancreatitis, in overlap syndrome of systemic sclerosis and systemic lupus erythematosus, successfully treated with plasmapheresis. ( Hara, M; Kamatani, N; Koizumi, K; Okamoto, H; Suzuki, Y; Tateishi, M, 2006) |
| "We report a case of acute pancreatitis, which occurred after delivery in a woman who had an uneventful course of pregnancy and parturition." | 1.32 | Acute pancreatitis occurring in the early postpartum period: a case report. ( Chaen, H; Eguchi, F; Fukami, T; Imura, H; Sudou, K, 2003) |
| "Gabexate mesilate was infused intravenously 6 hours after the initiation of induction of acute pancreatitis at doses of 0." | 1.30 | Gabexate mesilate improves pancreatic microcirculation and reduces lung edema in a rat model of acute pancreatitis. ( Chen, HM; Chen, MF; Shyr, MH, 1997) |
| "Pancreatitis was induced in 6-week-old male SPF Sprague-Dawley rats by two intravenous (i." | 1.30 | Induction of apoptosis with an extract of Artemisia asiatica attenuates the severity of cerulein-induced pancreatitis in rats. ( Ahn, BO; Cho, SW; Hahm, KB; Kim, JH; Kim, WB; Kim, YS; Yim, H; You, BM, 1998) |
| "Antiprotease has long been used for the treatment of acute pancreatitis, although its effects and mechanism have not been fully elucidated." | 1.29 | The effect of gabexate mesilate on pancreatic and hepatic microcirculation in acute experimental pancreatitis in rats. ( Chen, HM; Chen, MF; Hwang, TL, 1996) |
| "Acute pancreatitis was induced in 19 anesthetized dogs by retrograde injection of bile mixed with trypsin into the pancreatic duct." | 1.28 | Synthetic antiproteases in acute pancreatitis: an experimental study. ( Babicki, A; Basiński, A; Dobosz, M; Juszkiewicz, P; Sledziński, Z; Wajda, Z, 1992) |
| "Acute pancreatitis was induced in ten anesthetized dogs by retrograde injection for bile mixed with trypsin into the pancreatic duct." | 1.28 | Effect on hemodynamics of therapeutic infusion of gabexate mesilate (FOY) in experimental acute pancreatitis. ( Babicki, A; Basiński, A; Dobosz, M; Sledziński, Z; Stanek, A; Wajda, Z, 1989) |
| "Comparing the two groups of acute pancreatitis patients after 6 days of treatment with gabexate mesilate, we observed a statistically significantly lower alpha-amylase activity in the serum of treated patients compared with the placebo group." | 1.27 | Gabexate mesilate and camostate: new inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis. ( Freise, J; Magerstedt, P; Schmid, K; Schmidt, FW, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (15.83) | 18.7374 |
| 1990's | 50 (35.97) | 18.2507 |
| 2000's | 50 (35.97) | 29.6817 |
| 2010's | 13 (9.35) | 24.3611 |
| 2020's | 4 (2.88) | 2.80 |
| Authors | Studies |
|---|---|
| Song, Q | 2 |
| Gao, H | 1 |
| Wu, W | 1 |
| Gao, Y | 1 |
| Yang, J | 1 |
| Jiao, Z | 1 |
| Luo, Y | 1 |
| Chiu, YJ | 1 |
| Chen, SC | 1 |
| Kang, YN | 2 |
| Hou, SK | 1 |
| Chao, CC | 1 |
| Chang, CC | 2 |
| Xie, J | 1 |
| Li, L | 1 |
| Guglielmi, V | 1 |
| Tutino, M | 1 |
| Guerra, V | 1 |
| Giorgio, P | 1 |
| Kim, SC | 1 |
| Yang, HR | 1 |
| Sung, HY | 1 |
| Kim, JI | 1 |
| Lee, HJ | 1 |
| Cho, HJ | 1 |
| Cheung, DY | 1 |
| Kim, SS | 1 |
| Cho, SH | 1 |
| Kim, JK | 1 |
| Seta, T | 2 |
| Noguchi, Y | 2 |
| Shikata, S | 2 |
| Nakayama, T | 1 |
| Cofini, M | 1 |
| Favoriti, P | 1 |
| Quadrozzi, F | 1 |
| Jia, D | 1 |
| Yamamoto, M | 1 |
| Otsuki, M | 2 |
| Gao, HJ | 1 |
| Lv, FQ | 1 |
| Wang, S | 1 |
| Wang, YR | 1 |
| Luo, YK | 1 |
| Mei, XG | 1 |
| Tang, J | 1 |
| Wang, G | 1 |
| Liu, Y | 1 |
| Zhou, SF | 1 |
| Qiu, P | 1 |
| Xu, L | 1 |
| Wen, P | 1 |
| Wen, J | 1 |
| Xiao, X | 1 |
| Ino, Y | 1 |
| Arita, Y | 3 |
| Akashi, T | 2 |
| Kimura, T | 2 |
| Igarashi, H | 1 |
| Oono, T | 3 |
| Furukawa, M | 2 |
| Kawabe, K | 3 |
| Ogoshi, K | 1 |
| Ouchi, J | 1 |
| Miyahara, T | 1 |
| Takayanagi, R | 1 |
| Ito, T | 5 |
| Arata, S | 1 |
| Takada, T | 1 |
| Hirata, K | 2 |
| Yoshida, M | 1 |
| Mayumi, T | 1 |
| Hirota, M | 2 |
| Yokoe, M | 1 |
| Kiriyama, S | 1 |
| Sekimoto, M | 1 |
| Amano, H | 1 |
| Wada, K | 1 |
| Kimura, Y | 1 |
| Gabata, T | 1 |
| Takeda, K | 3 |
| Kataoka, K | 3 |
| Tanaka, M | 1 |
| Zhang, ZF | 1 |
| Yang, N | 1 |
| Zhao, G | 1 |
| Zhu, L | 1 |
| Zhu, Y | 1 |
| Wang, LX | 1 |
| Kwon, YH | 1 |
| Kim, JY | 1 |
| Lee, SJ | 1 |
| Jang, SY | 1 |
| Park, HW | 1 |
| Yang, HM | 1 |
| Jung, MK | 1 |
| Jeon, SW | 1 |
| Cho, CM | 1 |
| Tak, WY | 1 |
| Kweon, YO | 1 |
| Kim, SK | 1 |
| Oh, MJ | 1 |
| Kim, TN | 1 |
| Yasunaga, H | 1 |
| Horiguchi, H | 1 |
| Hashimoto, H | 1 |
| Matsuda, S | 1 |
| Fushimi, K | 1 |
| Andriulli, A | 5 |
| Clemente, R | 2 |
| Solmi, L | 2 |
| Terruzzi, V | 2 |
| Suriani, R | 1 |
| Sigillito, A | 1 |
| Leandro, G | 4 |
| Leo, P | 2 |
| De Maio, G | 2 |
| Perri, F | 3 |
| Hama, Y | 1 |
| Iwasaki, Y | 1 |
| Kaji, T | 1 |
| Hatsuse, K | 1 |
| Kusano, S | 1 |
| Woods, CM | 1 |
| Mawe, GM | 1 |
| Shaffer, EA | 1 |
| Toouli, J | 1 |
| T P Saccone, G | 1 |
| Pelagotti, F | 1 |
| Cecchi, M | 1 |
| Messori, A | 2 |
| Matsukawa, Y | 1 |
| Nishinarita, S | 1 |
| Sawada, S | 1 |
| Horie, T | 1 |
| Suto, S | 1 |
| Okuaki, Y | 1 |
| Matsuoka, M | 1 |
| Enomoto, Y | 1 |
| Tsuruta, Y | 1 |
| Miyagawa, Y | 1 |
| Saito, A | 1 |
| Aizawa, Y | 1 |
| Toda, G | 1 |
| Fukami, T | 1 |
| Chaen, H | 1 |
| Imura, H | 1 |
| Sudou, K | 1 |
| Eguchi, F | 1 |
| Masci, E | 5 |
| Cavallini, G | 5 |
| Mariani, A | 4 |
| Frulloni, L | 3 |
| Testoni, PA | 2 |
| Curioni, S | 2 |
| Tittobello, A | 2 |
| Uomo, G | 2 |
| Costamagna, G | 1 |
| Zambelli, S | 1 |
| Macarri, G | 1 |
| Innocenti, P | 1 |
| Dragonetti, C | 2 |
| Kamisawa, T | 1 |
| Jiang, PH | 1 |
| Motoo, Y | 2 |
| Iovanna, JL | 2 |
| Pébusque, MJ | 1 |
| Xie, MJ | 2 |
| Okada, G | 1 |
| Sawabu, N | 2 |
| Loperfido, S | 1 |
| Festa, V | 3 |
| Belmonte, A | 1 |
| Spirito, F | 2 |
| Silla, M | 1 |
| Forte, G | 1 |
| Marenco, G | 1 |
| Ciliberto, E | 1 |
| Sabatino, A | 1 |
| Monica, F | 1 |
| Magnolia, MR | 1 |
| Inoue, N | 1 |
| Gibo, J | 2 |
| Nawata, H | 3 |
| Funakoshi, A | 1 |
| Hisano, T | 1 |
| Inoue, M | 1 |
| Fujimori, N | 1 |
| Kohsaki, T | 1 |
| Nishimori, I | 1 |
| Onishi, S | 1 |
| Shimada, T | 1 |
| Fukui, T | 1 |
| Banfi, R | 1 |
| Borselli, G | 1 |
| Cappelletti, S | 1 |
| Mari, L | 1 |
| Aiazzi, M | 1 |
| Taddei, V | 1 |
| Hoogerwerf, WA | 1 |
| Xiong, GS | 1 |
| Wu, SM | 1 |
| Zhang, XW | 1 |
| Ge, ZZ | 1 |
| Pezzilli, R | 1 |
| Fantini, L | 1 |
| Morselli-Labate, AM | 1 |
| Heinrich, S | 1 |
| Schäfer, M | 1 |
| Rousson, V | 1 |
| Clavien, PA | 1 |
| Hellmig, S | 1 |
| Fölsch, UR | 1 |
| Suzuki, Y | 1 |
| Okamoto, H | 1 |
| Koizumi, K | 1 |
| Tateishi, M | 1 |
| Hara, M | 1 |
| Kamatani, N | 1 |
| Famularo, G | 1 |
| Minisola, G | 1 |
| De Simone, C | 1 |
| Sakai, M | 1 |
| Harada, K | 1 |
| Matsumura, H | 1 |
| Takahashi, T | 1 |
| Koie, H | 1 |
| Yamaya, Y | 1 |
| Watari, T | 1 |
| Shibuya, H | 1 |
| Sato, T | 1 |
| Tokuriki, M | 1 |
| Hasegawa, A | 1 |
| Piscaglia, F | 1 |
| Righini, R | 1 |
| Tewelde, AG | 1 |
| Zheng, M | 1 |
| Chen, Y | 1 |
| Yang, X | 1 |
| Li, J | 1 |
| Zhang, Y | 1 |
| Zeng, Q | 1 |
| Ueki, T | 1 |
| Otani, K | 1 |
| Kawamoto, K | 1 |
| Shimizu, A | 1 |
| Fujimura, N | 1 |
| Sakaguchi, S | 1 |
| Matsui, T | 1 |
| Sato, Y | 1 |
| Okamura, S | 1 |
| Nakasono, M | 1 |
| Aoki, R | 1 |
| Nakamoto, J | 1 |
| Muguruma, N | 1 |
| Ito, S | 1 |
| Federici, T | 1 |
| Ippolito, A | 1 |
| Forlano, R | 1 |
| Iacobellis, A | 1 |
| Annese, V | 2 |
| Lee, JK | 1 |
| Park, JK | 1 |
| Yoon, WJ | 1 |
| Lee, SH | 1 |
| Lee, KH | 1 |
| Ryu, JK | 1 |
| Kim, YT | 1 |
| Yoon, YB | 1 |
| Ishikura, H | 1 |
| Nishimura, S | 1 |
| Matsunami, M | 1 |
| Tsujiuchi, T | 1 |
| Ishiki, T | 1 |
| Sekiguchi, F | 1 |
| Naruse, M | 1 |
| Nakatani, T | 1 |
| Kamanaka, Y | 1 |
| Kawabata, A | 1 |
| Rombolà, F | 1 |
| Bertuccio, SN | 1 |
| Manes, G | 1 |
| Ardizzone, S | 1 |
| Lombardi, G | 1 |
| Pieramico, O | 1 |
| Porro, GB | 1 |
| Rudin, D | 2 |
| Kiss, A | 1 |
| Wetz, RV | 1 |
| Sottile, VM | 1 |
| Tsujino, T | 1 |
| Kawabe, T | 1 |
| Omata, M | 1 |
| Lieb, JG | 1 |
| Draganov, PV | 1 |
| Jo, YJ | 1 |
| Choi, HS | 1 |
| Jun, DW | 1 |
| Lee, OY | 1 |
| Kang, JS | 1 |
| Park, IG | 1 |
| Jung, KH | 1 |
| Hahm, JS | 1 |
| Bang, UC | 1 |
| Semb, S | 1 |
| Nojgaard, C | 1 |
| Bendtsen, F | 1 |
| Tympner, F | 1 |
| Rösch, W | 1 |
| Freise, J | 3 |
| Hesse, B | 1 |
| Lankisch, PG | 3 |
| Kunze, H | 1 |
| Pederzoli, P | 3 |
| Falconi, M | 3 |
| Bassi, C | 3 |
| Yamaguchi, H | 1 |
| Goto, M | 1 |
| Nakano, I | 1 |
| Okumura, Y | 1 |
| Inoue, H | 1 |
| Fujiyama, Y | 1 |
| Bamba, T | 1 |
| Leonhardt, U | 2 |
| Seidensticker, F | 2 |
| Stöckmann, F | 3 |
| Creutzfeldt, W | 2 |
| Closa, D | 1 |
| Rosello-Catafau, J | 1 |
| Martrat, A | 1 |
| Hotter, G | 1 |
| Bulbena, O | 1 |
| Fernandez-Cruz, L | 1 |
| Gelpi, E | 1 |
| Rampazzo, R | 1 |
| Scroccaro, G | 1 |
| Olivato, R | 1 |
| Martini, N | 1 |
| Kisfalvi, K | 1 |
| Papp, M | 1 |
| Friess, H | 1 |
| Büchler, M | 3 |
| Gorácz, UG | 1 |
| Dabrowski, A | 1 |
| Gabryelewicz, A | 1 |
| Yamagiwa, I | 1 |
| Obata, K | 1 |
| Hatanaka, Y | 1 |
| Saito, H | 1 |
| Washio, M | 1 |
| Yoshida, T | 1 |
| Yamamoto, Y | 1 |
| Malfertheiner, P | 2 |
| Uhl, W | 3 |
| Schölmerich, J | 1 |
| Adler, G | 1 |
| Gaus, W | 1 |
| Rolle, K | 1 |
| Beger, HG | 2 |
| Warshaw, AL | 1 |
| Huibregtse, K | 1 |
| Sugiyama, M | 2 |
| Kobori, O | 1 |
| Atomi, Y | 2 |
| Wada, N | 2 |
| Kuroda, A | 2 |
| Muto, T | 2 |
| Mariana, A | 1 |
| Di Francesco, V | 2 |
| Schmid, S | 1 |
| Büchler, MW | 1 |
| Kim, KH | 1 |
| Lee, MG | 1 |
| Kim, DG | 1 |
| Chen, HM | 2 |
| Hwang, TL | 1 |
| Chen, MF | 2 |
| Taniguchi, H | 1 |
| Yomota, E | 1 |
| Kume, E | 1 |
| Shikano, T | 1 |
| Endo, T | 1 |
| Nagasaki, M | 1 |
| Pasricha, P | 1 |
| Nakayama, F | 1 |
| Schneider, J | 1 |
| Barkin, J | 1 |
| Ziebert, JJ | 1 |
| Bjorkman, DJ | 1 |
| Shyr, MH | 1 |
| Kimura, K | 1 |
| Tominaga, K | 1 |
| Fujii, M | 1 |
| Saito, T | 1 |
| Kasai, H | 1 |
| Sasaki, T | 1 |
| Yorizumi, H | 1 |
| Sakagami, J | 1 |
| Kashima, K | 2 |
| Tagami, H | 1 |
| Abe, S | 1 |
| Yoshida, Y | 1 |
| Tanaka, I | 1 |
| Kamei, C | 1 |
| Caruso, N | 1 |
| Lezzi, G | 1 |
| Lichino, E | 1 |
| Bruno, F | 1 |
| Hahm, KB | 1 |
| Kim, JH | 1 |
| You, BM | 1 |
| Kim, YS | 1 |
| Cho, SW | 1 |
| Yim, H | 1 |
| Ahn, BO | 1 |
| Kim, WB | 1 |
| Otani, T | 1 |
| Yuasa, C | 1 |
| Irimura, K | 1 |
| Oda, M | 1 |
| Fukui, K | 1 |
| Oka, T | 1 |
| Niro, G | 1 |
| Mangia, A | 1 |
| Gambassi, G | 1 |
| Villani, MR | 1 |
| Facciorusso, D | 1 |
| Conoscitore, P | 1 |
| Haber, GB | 1 |
| Heyries, L | 1 |
| Su, SB | 1 |
| Baillie, J | 1 |
| Angelini, G | 1 |
| Talamini, G | 1 |
| Passaretti, S | 1 |
| Testoni, P | 1 |
| Kusterer, K | 1 |
| Enghofer, M | 1 |
| Poschmann, T | 1 |
| Usadel, KH | 1 |
| Umehara, K | 1 |
| Hirano, T | 3 |
| Manabe, T | 4 |
| Tobe, T | 3 |
| Valderrama, R | 1 |
| Pérez-Mateo, M | 1 |
| Navarro, S | 1 |
| Vázquez, N | 1 |
| Sanjosé, L | 1 |
| Adrián, MJ | 1 |
| Estruch, J | 1 |
| Murakawa, M | 1 |
| Okamura, T | 1 |
| Shibuya, T | 1 |
| Harada, M | 1 |
| Otsuka, T | 1 |
| Niho, Y | 1 |
| Tani, S | 1 |
| Okabayashi, Y | 1 |
| Fuji, M | 1 |
| Nakamura, T | 1 |
| Fujisawa, T | 1 |
| Itoh, H | 1 |
| Yoshida, K | 1 |
| Toki, F | 1 |
| Takeuchi, T | 1 |
| Dobosz, M | 2 |
| Sledziński, Z | 2 |
| Babicki, A | 2 |
| Juszkiewicz, P | 1 |
| Basiński, A | 2 |
| Wajda, Z | 2 |
| Harada, H | 1 |
| Miyake, H | 1 |
| Ochi, K | 1 |
| Tanaka, J | 1 |
| Kimura, I | 1 |
| Benetti, L | 1 |
| Girelli, R | 1 |
| Nifosí, F | 1 |
| Coviello, G | 1 |
| Vesentini, S | 1 |
| Tamura, K | 1 |
| Sweiry, JH | 1 |
| Mann, GE | 1 |
| Heitz, J | 1 |
| Semsch, B | 1 |
| Emde, C | 1 |
| Jansen, U | 1 |
| Schäfer, JH | 1 |
| Fussek, M | 1 |
| Schmidt, FW | 2 |
| Magerstedt, P | 1 |
| Schmid, K | 1 |
| Niederau, C | 3 |
| Liddle, RA | 1 |
| Ferrell, LD | 3 |
| Grendell, JH | 3 |
| Wisner, JR | 1 |
| Renner, IG | 1 |
| Ohshio, G | 1 |
| Saluja, AK | 1 |
| Leli, U | 1 |
| Sengupta, A | 1 |
| Steer, ML | 1 |
| Wakayama, T | 1 |
| Itoh, T | 1 |
| Shibayama, K | 1 |
| Idezuki, Y | 1 |
| Kahle, M | 2 |
| König, H | 1 |
| Filler, RD | 1 |
| Ristkari, SK | 1 |
| Rämö, OJ | 1 |
| Kiviniemi, H | 1 |
| Gröhn, P | 1 |
| Mahlberg, K | 1 |
| Mokka, RE | 1 |
| Stanek, A | 1 |
| Mikata, N | 1 |
| Imao, S | 1 |
| Tanaka, Y | 1 |
| Horiuchi, D | 1 |
| Matsumoto, G | 1 |
| Hasegawa, K | 1 |
| Redmond, HP | 1 |
| Leahy, AL | 1 |
| Keane, FB | 1 |
| Tanner, WA | 1 |
| Pohl, U | 2 |
| Göke, B | 1 |
| Otto, J | 2 |
| Wereszczynska-Siemiatkowska, U | 1 |
| Gröne, HJ | 1 |
| Rahlf, G | 1 |
| Melzer, P | 1 |
| Horbach, L | 1 |
| Yang, CY | 1 |
| Chang-Chien, CS | 1 |
| Liaw, YF | 1 |
| Wolf, HR | 1 |
| Schwab, G | 1 |
| Crass, RA | 1 |
| Silver, G | 1 |
| Yamasaki, Y | 1 |
| Kuroshima, T | 1 |
| Tsuji, K | 1 |
| Kawamoto, H | 1 |
| Higashimoto, Y | 1 |
| Klein, U | 1 |
| König, W | 1 |
| Martin, U | 1 |
| Alles, JU | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fistulotomy as the Primary Cannulation Technique for All Patients Undergoing ERCP: A Randomized, Controlled Trial[NCT04559867] | 538 participants (Anticipated) | Interventional | 2020-09-10 | Recruiting | |||
| Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) - Induced Pancreatitis Using Aggressive Lactated Ringer's Infusion and/or Rectal Indomethacin[NCT02641561] | Phase 3 | 192 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Tailored Hydration for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis[NCT03561441] | 350 participants (Actual) | Interventional | 2019-01-01 | Completed | |||
| Feasibility Study of a Randomized Trial of Aggressive Fluid Hydration to Prevent Post ERCP Pancreatitis[NCT01758549] | 62 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| A Phase II Study to Establish the Efficacy of Synthetic Human SecretiN in Human Acute Pancreatitis (SNAP) Study[NCT03686618] | Phase 2 | 40 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | days (Mean) |
|---|---|
| A (NS+Placebo) | 2.3 |
| B (NS+IND) | 2.2 |
| C (LR+Placebo) | 1.9 |
| D (LR+IND) | 4.3 |
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 6 |
| B (NS+IND) | 2 |
| C (LR+Placebo) | 2 |
| D (LR+IND) | 1 |
amylase or lipase (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 1 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 1 |
bilateral opacities on chest imaging not explained by other lung pathology, respiratory failure not explained by heart failure or volume, and overload and a pulmonary arterial oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio under 300, PaO2/FiO2 ratio is the partial pressure arterial oxygen and fraction of inspired oxygen (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 1 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 1 |
| B (NS+IND) | 2 |
| C (LR+Placebo) | 2 |
| D (LR+IND) | 1 |
creatinine > 1.5 milligrams/deciliter (mg/dL) (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 1 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
INR > 1.5 (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 1 |
Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 6 |
| B (NS+IND) | 2 |
| C (LR+Placebo) | 2 |
| D (LR+IND) | 1 |
positive blood culture (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
> 10% immature neutrophils (band forms). (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
Heart rate > 90 beats per minutes (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
PaCO2 < 4.3 kilopascal (kPa) (32 mmHg) (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
Respiratory rate > 20 breaths per minute (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
Temperature < 36°C(96.8°F) or > 38°C(100.4°F) (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
white blood cell (WBC) count < 4000 cells/mm³ (4 x 109 cells/L) (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
29 reviews available for gabexate and Pancreatitis
| Article | Year |
|---|---|
Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized clinical trials.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Humans; Pancreatitis; Randomized Controll | 2021 |
Treatment of acute pancreatitis with protease inhibitors administered through intravenous infusion: an updated systematic review and meta-analysis.
Topics: Acute Disease; Aprotinin; Gabexate; Humans; Infusions, Intravenous; Pancreatitis; Protease Inhibitor | 2014 |
Preventive effect of ulinastatin and gabexate mesylate on post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Glycoproteins; Humans; Pancreatitis | 2010 |
Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
Topics: Acute Disease; Adult; Cholangiopancreatography, Endoscopic Retrograde; Clinical Competence; Double-B | 2002 |
Effects of bioactive agents on biliary motor function.
Topics: Animals; Biliary Tract; Electroacupuncture; Gabexate; Gallbladder; Gallbladder Emptying; Histamine; | 2003 |
Use of gabexate mesylate in Italian hospitals: a multicentre observational study.
Topics: Acute Disease; Aged; Drug Utilization Review; Female; Gabexate; Humans; Inpatients; Italy; Male; Mid | 2003 |
[A case of groove pancreatitis pure type treated with conservative therapy].
Topics: Chronic Disease; Drug Therapy, Combination; Esters; Gabexate; Guanidines; Humans; Magnetic Resonance | 2003 |
[Evidence-based therapeutic guidelines for severe acute pancreatitis].
Topics: Acute Disease; Anti-Bacterial Agents; Decontamination; Disinfection; Drug Therapy, Combination; Evid | 2004 |
[Autoimmune pancreatitis].
Topics: Autoimmune Diseases; Diagnostic Imaging; Diet, Fat-Restricted; Drainage; Esters; Fasting; Gabexate; | 2004 |
[Essential therapeutic strategies for acute pancreatitis--guidelines for initial treatment and their significance].
Topics: Acute Disease; Analgesics, Opioid; Antibiotic Prophylaxis; Biopsy, Fine-Needle; Buprenorphine; Criti | 2004 |
[Treatment of acute pancreatitis with protease inhibitor, H2 receptor antagonist and somatostatin analogue].
Topics: Acute Disease; Aprotinin; Benzamidines; Cimetidine; Drug Administration Schedule; Drug Therapy, Comb | 2004 |
Treatment of acute pancreatitis with protease inhibitors: a meta-analysis.
Topics: Abdominal Abscess; Acute Disease; Aprotinin; Gabexate; Humans; Pancreatic Pseudocyst; Pancreatitis; | 2004 |
Pharmacological management of pancreatitis.
Topics: Animals; Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Glycoproteins; Humans; Octreotid | 2005 |
Evidence-based treatment of acute pancreatitis: a look at established paradigms.
Topics: Acute Disease; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aprotinin; Cholecystectomy; Enteral Nu | 2006 |
Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Topics: Acute Disease; Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Humans; Linear Models; Odd | 2007 |
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Hormones; Humans; Hyperamylasemia; Pancre | 2007 |
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Hormones; Humans; Hyperamylasemia; Pancre | 2007 |
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Hormones; Humans; Hyperamylasemia; Pancre | 2007 |
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Hormones; Humans; Hyperamylasemia; Pancre | 2007 |
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Hormones; Humans; Hyperamylasemia; Pancre | 2007 |
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Hormones; Humans; Hyperamylasemia; Pancre | 2007 |
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Hormones; Humans; Hyperamylasemia; Pancre | 2007 |
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Hormones; Humans; Hyperamylasemia; Pancre | 2007 |
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Hormones; Humans; Hyperamylasemia; Pancre | 2007 |
Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Humans; Pancreatitis; Randomized Controll | 2007 |
Antiproteases in preventing post-ERCP acute pancreatitis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Glycoproteins; Humans; Pancreatitis; Rand | 2007 |
Early successes and late failures in the prevention of post endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Antioxidants; Cholangiopancreatography, Endoscopic | 2007 |
Pharmacological approach to acute pancreatitis.
Topics: Acute Disease; Adrenal Cortex Hormones; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, No | 2008 |
Effectiveness of gabexate mesilate in acute pancreatitis. A metaanalysis.
Topics: Acute Disease; Gabexate; Humans; Pancreatitis | 1995 |
[Clinical study of chronic pancreatitis].
Topics: Alcohol Drinking; Cholangiopancreatography, Endoscopic Retrograde; Chronic Disease; Esters; Fasting; | 1993 |
Damage prevention versus damage control in acute pancreatitis.
Topics: Acute Disease; Gabexate; Humans; Pancreatitis | 1993 |
Protease-antiprotease interactions and the rationale for therapeutic protease inhibitors.
Topics: Acute Disease; alpha 1-Antitrypsin; alpha-Macroglobulins; Animals; Aprotinin; Clinical Trials as Top | 1996 |
Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis.
Topics: Acute Disease; Anticoagulants; Clinical Trials as Topic; Gabexate; Hormone Antagonists; Hormones; Hu | 1998 |
[Synthetic protease inhibitors for human acute pancreatitis].
Topics: Acute Disease; Animals; Aprotinin; Cholangiopancreatography, Endoscopic Retrograde; Europe; Gabexate | 1998 |
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
Topics: Acute Disease; Amylases; Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Hormones; Humans | 2000 |
[Can post-ERCP acute pancreatitis be predicted and prevented?].
Topics: Acute Disease; Adrenal Cortex Hormones; Cholangiopancreatography, Endoscopic Retrograde; Contrast Me | 2001 |
Predicting and preventing post-ERCP pancreatitis.
Topics: Acute Disease; Acute-Phase Proteins; Amylases; Biomarkers; Calcitonin; Cholangiopancreatography, End | 2002 |
18 trials available for gabexate and Pancreatitis
| Article | Year |
|---|---|
Effect of Somatostatin, Ulinastatin and Gabexate on the Treatment of Severe Acute Pancreatitis.
Topics: Acute Disease; Adult; Double-Blind Method; Drug Therapy, Combination; Female; Gabexate; Glycoprotein | 2016 |
[Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?].
Topics: Adult; Aged; Aged, 80 and over; Benzamidines; Cholangiopancreatography, Endoscopic Retrograde; Femal | 2012 |
Prospective comparative study of endoscopic papillary large balloon dilation and endoscopic sphincterotomy for removal of large bile duct stones in patients above 45 years of age.
Topics: Aged; Aged, 80 and over; Ampulla of Vater; Anticoagulants; Catheterization; Chi-Square Distribution; | 2012 |
Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
Topics: Acute Disease; Adult; Cholangiopancreatography, Endoscopic Retrograde; Clinical Competence; Double-B | 2002 |
Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Biliary Tract Diseases; Cholangiopancreat | 2003 |
Short-term prophylactic prevention of post-ERCP pancreatitis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Humans; Pancreatitis; Somatostatin | 2003 |
Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate.
Topics: Aged; Aged, 80 and over; Chemoprevention; Cholangiopancreatography, Endoscopic Retrograde; Double-Bl | 2004 |
Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Abdominal Pain; Acute Disease; Cholangiopancreatography, Endoscopic Retrograde; Double-Blind Method; | 2006 |
Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial.
Topics: Aged; Cholangiopancreatography, Endoscopic Retrograde; Female; Gabexate; Glycoproteins; Humans; Male | 2007 |
Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Cholangiopancreatography, Endoscopic Retrograde; Dose-Response Relat | 2007 |
[Effect of secretin and gabexate-mesilate (synthetic protease inhibitor) on serum amylase level after ERCP].
Topics: Alkaline Phosphatase; Amylases; Cholangiopancreatography, Endoscopic Retrograde; Chronic Disease; Do | 1982 |
Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.). A prospective, randomized, double-blind multicenter study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aprotinin; Double-Blind Method; Female; Gabexate; Hum | 1993 |
Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group.
Topics: Acute Disease; Adult; Aged; Double-Blind Method; Female; Gabexate; Humans; Male; Middle Aged; Pancre | 1993 |
Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
Topics: Acute Disease; Adult; Aged; Amylases; Cholangiopancreatography, Endoscopic Retrograde; Double-Blind | 1996 |
Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis.
Topics: Acute Disease; Double-Blind Method; Female; Gabexate; Humans; Male; Middle Aged; Pancreatitis; Prosp | 1992 |
Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis.
Topics: Acute Disease; Female; Gabexate; Humans; Male; Middle Aged; Pancreatitis; Protease Inhibitors; Survi | 1991 |
[Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients].
Topics: Acute Disease; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Gabexate; Germany, West | 1986 |
Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis.
Topics: Acute Disease; Clinical Trials as Topic; Female; Gabexate; Guanidines; Humans; Male; Pancreatitis; P | 1987 |
93 other studies available for gabexate and Pancreatitis
| Article | Year |
|---|---|
Gabexate Mesylate-Poloxamer 407 Conjugate Alleviates Sodium Taurocholate-Induced Severe Acute Pancreatitis in an Optimized Rat Model.
Topics: Acute Disease; Animals; Gabexate; Interleukin-6; Pancreas; Pancreatitis; Poloxamer; Rats; Rats, Spra | 2023 |
Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized clinical trials.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Humans; Pancreatitis; Randomized Controll | 2021 |
Response to letter to the editor: Appropriate data synthesis provide reliable evidence regarding efficacy of FOY in preventing post endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Humans; Pancreatitis; Stents | 2021 |
Rectal indomethacin or intravenous gabexate mesylate as prophylaxis for acute pancreatitis post-endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Administration, Intravenous; Administration, Rectal; Aged; Aged, 80 and over; Anti-In | 2017 |
Clinical efficacy of gabexate mesilate for acute pancreatitis in children.
Topics: Acute Disease; Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Gabexate; | 2013 |
Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infectio | 2014 |
[Acute pancreatitis in pediatric age: our experience in 52 cases].
Topics: Acute Disease; Adolescent; Amylases; Biomarkers; Child; Child, Preschool; Cholangiopancreatography, | 2014 |
Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats.
Topics: Administration, Oral; Animals; Biomarkers; Bombesin; Cell Proliferation; Cholecystokinin; Disease Mo | 2015 |
A novel thermosensitive in-situ gel of gabexate mesilate for treatment of traumatic pancreatitis: An experimental study.
Topics: Amylases; Animals; C-Reactive Protein; Delayed-Action Preparations; Gabexate; Gels; Male; Muscle, Sk | 2015 |
Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Anti-Bacterial Agents; C-Reactive Protein; Drug Therapy, | 2008 |
Post-ERCP pancreatitis.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograd | 2010 |
Effect and cost of treatment for acute pancreatitis with or without gabexate mesylate: a propensity score analysis using a nationwide administrative database.
Topics: Acute Disease; Adult; Aged; Chi-Square Distribution; Cost-Benefit Analysis; Drug Costs; Female; Gabe | 2013 |
Coil compaction after embolization of the superior mesenteric artery pseudoaneurysm.
Topics: Acute Disease; Aneurysm, False; Embolization, Therapeutic; Gabexate; Hematemesis; Humans; Male; Mese | 2002 |
Fatal cases of gabexate mesilate-induced anaphylaxis.
Topics: Anaphylaxis; Fatal Outcome; Female; Gabexate; Humans; Male; Middle Aged; Pancreatitis; Serine Protei | 2002 |
Acute pancreatitis occurring in the early postpartum period: a case report.
Topics: Abdominal Pain; Acute Disease; Adolescent; Back Pain; Famotidine; Female; Gabexate; Histamine H2 Ant | 2003 |
Tumor protein p53-induced nuclear protein 1 (TP53INP1) in spontaneous chronic pancreatitis in the WBN/Kob rat: drug effects on its expression in the pancreas.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Arginine; Carrier Proteins; Cell Line; Chronic Di | 2004 |
Acute pancreatitis in the early stages of pregnancy associated with a PSTI gene mutation.
Topics: Abdominal Pain; Acute Disease; Adult; Amino Acid Substitution; Amylases; Carrier Proteins; Diet, Fat | 2004 |
Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity.
Topics: Animals; Cell Proliferation; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Dru | 2005 |
Gabexate mesilate and acute pancreatitis: an experience of evidence based drug information for improving rational drug use.
Topics: Acute Disease; Anticoagulants; Dose-Response Relationship, Drug; Drug Information Services; Drug Pre | 2005 |
New approaches for the treatment of acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Antibodies, Monoclonal; Cholangiopancreatography, Endoscopic Retro | 2006 |
Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amylases; Child; Child, Preschool; Cholangiopancreatogra | 2006 |
Pharmacological prevention of post-ERCP pancreatitis--an everlasting dream?
Topics: Cholangiopancreatography, Endoscopic Retrograde; Cost-Benefit Analysis; Gabexate; Humans; Hyperamyla | 2006 |
A case of severe acute pancreatitis, in overlap syndrome of systemic sclerosis and systemic lupus erythematosus, successfully treated with plasmapheresis.
Topics: Adult; Anti-Inflammatory Agents; Female; Gabexate; Humans; Lupus Erythematosus, Systemic; Methylpred | 2006 |
Acute pancreatitis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Cost-Benefit Analysis; Gabexate; Humans; Infusions, | 2006 |
A case of feline pancreatitis.
Topics: Animals; Anti-Inflammatory Agents; Cat Diseases; Cats; Female; Gabexate; Pancreatitis; Prednisolone; | 2006 |
Prophylaxis of post-ERCP pancreatic complications with gabexate.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Clinical Protocols; Gabexate; Humans; Pancreatitis; | 2007 |
Evaluation of serum amylase and gabexate mesilate with endoscopic papillary balloon dilatation.
Topics: Acute Disease; Aged; Amylases; Catheterization; Endoscopy, Digestive System; Female; Gabexate; Galls | 2007 |
Risk for post-ERCP pancreatitis after needle knife precut sphincterotomy following repeated cannulation attempts.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Catheterization; Cholangiopancreatography, Endoscopic | 2007 |
The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents.
Topics: Abdominal Pain; Animals; Ceruletide; Dose-Response Relationship, Drug; Esters; Gabexate; Guanidines; | 2007 |
[Typhoid fever and acute pancreatitis: two cases].
Topics: Abdominal Pain; Acute Disease; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Ceftriaxone; Female; | 2007 |
Somatostatin bolus injection for post-ERCP pancreatitis prevention: a need for further study.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Humans; Injections; Pancreatitis; Serine | 2008 |
The effects of a new human leukocyte elastase inhibitor (recombinant guamerin) on cerulein-induced pancreatitis in rats.
Topics: Amylases; Animals; Ceruletide; Cytokines; Gabexate; Glycoproteins; Invertebrate Hormones; Leukocyte | 2008 |
[Therapy of acute pancreatitis with a synthetic protease and phospholipase A2 inhibitor gabexate mesilate].
Topics: Acute Disease; Adult; Aged; Amylases; Female; Gabexate; Guanidines; Humans; Male; Middle Aged; Pancr | 1983 |
Effects of the serine protease inhibitor gabexate mesilate on purified pancreatic phospholipase A2.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Gabexate; Guanidines; Pancreas; Pancreatitis; Phosphol | 1984 |
Protective effects of gabexate mesilate on acute pancreatitis induced by tacrolimus (FK-506) in rats in which the pancreas was stimulated by caerulein.
Topics: Amylases; Animals; Ceruletide; Gabexate; Male; Pancreas; Pancreatic Elastase; Pancreatitis; Rats; Ra | 1994 |
Effects of serine protease inhibitors on accumulation of polymorphonuclear leukocytes in the lung induced by acute pancreatitis in rats.
Topics: Acute Disease; Animals; Cell Adhesion; Cell Movement; Cells, Cultured; Disease Models, Animal; Endot | 1995 |
Effect of camostate administration for two weeks on experimental pancreatitis in mice and rats.
Topics: Administration, Oral; Amylases; Animals; Cholecystokinin; Esters; Female; Gabexate; Guanidines; Male | 1993 |
Changes of systemic prostacyclin and thromboxane A2 in sodium taurocholate- and cerulein-induced acute pancreatitis in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Acute Disease; Amylases; Animals; Ceruletide; Epoprostenol; Gabexate; | 1993 |
Beneficial effects of preventive oral administration of camostate on cerulein-induced pancreatitis in rats.
Topics: Administration, Oral; Animals; Ceruletide; Esters; Gabexate; Guanidines; Pancreatitis; Rats; Rats, W | 1995 |
The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis.
Topics: Acute Disease; Animals; Benzamidines; Gabexate; Guanidines; Lung; Male; Malondialdehyde; Oxidative S | 1994 |
Ischemic colitis complicating severe acute pancreatitis in a child.
Topics: Acute Disease; Child, Preschool; Colitis, Ischemic; Colon; Colonoscopy; Female; Gabexate; Humans; Pa | 1993 |
Gabexate mesilate in human acute pancreatitis.
Topics: Acute Disease; Gabexate; Humans; Pancreatitis | 1993 |
Complications of endoscopic sphincterotomy and their prevention.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Clinical Competence; Gabexate; Humans; Pancreatitis | 1996 |
Effect of oral administration of protease inhibitor on pancreatic exocrine function in WBN/Kob rats with chronic pancreatitis.
Topics: Administration, Oral; Animals; Cholecystokinin; Chronic Disease; Disease Models, Animal; Esters; Gab | 1996 |
The cholecystokinin receptor antagonist L-364,718 reduces taurocholate-induced pancreatitis in rats.
Topics: Amylases; Animals; Benzodiazepinones; Cholagogues and Choleretics; Devazepide; Esters; Gabexate; Gua | 1996 |
The effect of gabexate mesilate on pancreatic and hepatic microcirculation in acute experimental pancreatitis in rats.
Topics: Acute Disease; Animals; Ceruletide; Disease Models, Animal; Endothelium, Vascular; Gabexate; Leukocy | 1996 |
Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Disease Models, Animal; Dogs; Esters; Female; Gabexate | 1997 |
Prevention of ERCP-induced pancreatitis: success at last.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Double-Blind Method; Gabexate; Humans; Pancreatitis | 1997 |
Panniculitis with eosinophilic infiltration due to gabexate mesilate (FOY): possibility of allergic reaction.
Topics: Acute Disease; Blood Proteins; Connective Tissue; Cytoplasmic Granules; Drug Eruptions; Eosinophil G | 1997 |
Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Humans; Pancreas; Pancreat | 1997 |
Protease inhibitors for prevention of ERCP pancreatitis: can we afford the price of success?
Topics: Cholangiopancreatography, Endoscopic Retrograde; Costs and Cost Analysis; Drug Costs; Gabexate; Huma | 1997 |
Effect of oral protease inhibitor administration on gallbladder motility in patients with mild chronic pancreatitis.
Topics: Administration, Oral; Adult; Aged; Cholecystokinin; Chronic Disease; Esters; Female; Gabexate; Gallb | 1997 |
Gabexate mesilate improves pancreatic microcirculation and reduces lung edema in a rat model of acute pancreatitis.
Topics: Acute Disease; Animals; Gabexate; Male; Microcirculation; Pancreas; Pancreatitis; Pulmonary Edema; R | 1997 |
Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Duodenum; Female; Gabexate; Hormone Antagonists; Injec | 1998 |
Pathophysiologic studies of experimental chronic pancreatitis in rats induced by injection of zein-oleic acid-linoleic acid solution into the pancreatic duct.
Topics: Amylases; Animals; Blood Glucose; Body Weight; Chronic Disease; Disease Models, Animal; Esters; Gabe | 1998 |
Effect of methylcarbonylmethyl 2(S)-[4-(4-guanidino-benzoyloxy)phenyl] propionate methanesulfonate (TT-S24) on experimental pancreatitis in rats.
Topics: Amylases; Animals; Ceruletide; Disease Models, Animal; Esters; Gabexate; Guanidines; Male; Pancreati | 1998 |
Induction of apoptosis with an extract of Artemisia asiatica attenuates the severity of cerulein-induced pancreatitis in rats.
Topics: Acute Disease; Amylases; Animals; Apoptosis; Artemisia; Ceruletide; DNA Fragmentation; Gabexate; Lip | 1998 |
Oral administration of sepimostat mesilate prevents acute alcohol pancreatic injury in rats.
Topics: Acute Disease; Administration, Oral; Amylases; Animals; Ceruletide; Esters; Ethanol; Gabexate; Guani | 1999 |
Prevention of post-ERCP pancreatitis.
Topics: Cholangiopancreatography, Endoscopic Retrograde; Gabexate; Hormones; Humans; Octreotide; Pancreatiti | 2000 |
Effect of camostat mesilate on the expression of pancreatitis-associated protein (PAP), p8, and cytokines in rat spontaneous chronic pancreatitis.
Topics: Acute-Phase Proteins; Animals; Antigens, Neoplasm; Basic Helix-Loop-Helix Transcription Factors; Bio | 2001 |
Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility.
Topics: Acute Disease; Adult; Female; Gabexate; Humans; Male; Manometry; Middle Aged; Pancreatitis; Serine P | 2002 |
The effect of somatostatin, gabexate mesilate and dextran 40 on the microcirculation in sodium taurocholate-induced pancreatitis.
Topics: Animals; Capillary Permeability; Dextrans; Female; Fluorescein-5-isothiocyanate; Gabexate; Microcirc | 1992 |
[Treatment of acute pancreatitis].
Topics: Acute Disease; Benzamidines; Disseminated Intravascular Coagulation; Drainage; Gabexate; Glycoprotei | 1992 |
"Cocktail" therapy for acute pancreatitis: combined therapy of protease inhibitor, xanthine oxidase inhibitor and platelet activating factor antagonist in rat caerulein-induced pancreatis.
Topics: Acute Disease; Allopurinol; Animals; Ceruletide; Drug Therapy, Combination; Gabexate; Male; Pancreat | 1992 |
Protection by a new synthetic protease inhibitor, ONO3307, of the rat exocrine pancreas during acute edematous pancreatitis induced by a supramaximal dose of caerulein in comparison with FOY007.
Topics: Acute Disease; Amylases; Animals; Body Water; Cathepsin B; Ceruletide; Edema; Gabexate; Guanidines; | 1992 |
Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benz | 1992 |
Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Esters; Gabexate; Guanidines; Male; Organ Size; Pancre | 1990 |
[Antienzyme preparations in the treatment of acute pancreatitis].
Topics: Acute Disease; Adult; Aprotinin; Benzamidines; Cytidine Diphosphate Choline; Disseminated Intravascu | 1990 |
Protective effects of gabexate mesilate (FOY) against impaired pancreatic energy metabolism in rat acute pancreatitis induced by caerulein.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Gabexate; Malate Dehydrogenase; Male; Mitochondria; Pa | 1991 |
[Protease inhibitors in the treatment of pancreatitis].
Topics: Acute Disease; Animals; Aprotinin; Chronic Disease; Esters; Gabexate; Glycoproteins; Guanidines; Hum | 1991 |
Synthetic antiproteases in acute pancreatitis: an experimental study.
Topics: Acute Disease; Animals; Benzamidines; Dogs; Gabexate; Guanidines; Hemodynamics; Hemorrhage; Pancreat | 1992 |
Early graft injuries after pancreatic transplantation in syngeneic rats. Cytoprotective effects of gabexate-mesilate.
Topics: Analysis of Variance; Animals; Edema; Gabexate; Graft Survival; Necrosis; Organ Preservation; Pancre | 1991 |
[Effect of oxygen free radicals on the rat pancreas in vivo].
Topics: Acute Disease; Animals; Catalase; Free Radical Scavengers; Free Radicals; Gabexate; Hydrogen Peroxid | 1991 |
Pancreatic microvascular permeability in caerulein-induced acute pancreatitis.
Topics: Acute Disease; Animals; Capillary Permeability; Ceruletide; Edetic Acid; Endothelium, Vascular; Este | 1991 |
[The protease inhibitor gabexate mesilate in experimentally-induced acute pancreatitis with early gram-negative infection in the Göttingen minipig: therapeutic efficacy and effects on blood coagulation and fibrinolysis].
Topics: Acute Disease; Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Escherichia coli | 1990 |
Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis.
Topics: Acute Disease; Animals; Esters; Gabexate; Guanidines; Male; Pancreatitis; Peritoneal Lavage; Proteas | 1990 |
Gabexate mesilate and camostate: new inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis.
Topics: Acute Disease; alpha-Amylases; Aprotinin; Esters; Gabexate; Guanidines; Humans; Infusions, Parentera | 1985 |
Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Cholecystokinin; Choline Deficiency; Disease Models, Animal; Ethio | 1986 |
Gabexate mesilate (FOY) protects against ceruletide-induced acute pancreatitis in the rat.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Disease Models, Animal; Gabexate; Guanidines; Infusion | 1987 |
[The Pancreas Study Group: Inhibition of pancreas secretion and trypsin activity. Mechanisms and importance of therapy of acute and chronic pancreatitis].
Topics: Adult; Animals; Aprotinin; Bicarbonates; Cholecystokinin; Chronic Disease; Dogs; Female; Gabexate; G | 1987 |
Esterase inhibitors prevent lysosomal enzyme redistribution in two noninvasive models of experimental pancreatitis.
Topics: Amylases; Animals; Cathepsin B; Esters; Gabexate; Guanidines; Male; Pancreas; Pancreatitis; Protease | 1989 |
Prevention of the spread of experimental acute pancreatitis by intraductal administration of a synthetic protease inhibitor in dogs.
Topics: Amylases; Animals; Dogs; Female; Gabexate; Guanidines; Infusions, Intravenous; Kidney; Male; Pancrea | 1989 |
Lysolecithin concentration in pancreatic tissue during therapy with phospholipase A2-inhibitors in acute necrotizing pancreatitis.
Topics: Acute Disease; Animals; Chlorpromazine; Dogs; Dose-Response Relationship, Drug; Edetic Acid; Female; | 1989 |
The effect of gabexate mesilate on the outcome of acute hemorrhagic pancreatitis in pigs.
Topics: Acute Disease; Animals; Gabexate; Guanidines; Hemodynamics; Hemorrhage; Pancreatitis; Phospholipases | 1989 |
Effect on hemodynamics of therapeutic infusion of gabexate mesilate (FOY) in experimental acute pancreatitis.
Topics: Acute Disease; Animals; Dogs; Gabexate; Guanidines; Hemodynamics; Male; Pancreatitis; Prostaglandins | 1989 |
[A case of renal cancer complicated with acute hypercalcemia and acute pancreatitis].
Topics: Acute Disease; Calcitonin; Emergencies; Gabexate; Guanidines; Humans; Hypercalcemia; Kidney Neoplasm | 1989 |
Effect of FOY-305 (Camostate) on severe acute pancreatitis in two experimental animal models.
Topics: Acute Disease; Animals; Disease Models, Animal; Esters; Gabexate; Guanidines; Pancreatitis; Rats; Ra | 1989 |
Effect of FOY-305 (camostate) on severe acute pancreatitis in two experimental animal models.
Topics: Acute Disease; Animals; Choline Deficiency; Esters; Female; Gabexate; Guanidines; Male; Mice; Pancre | 1989 |
[Gabexate mesilate in the therapy of acute pancreatitis. Multicenter study of tolerance of a high intravenous dose (4 g/day)].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Evaluation; Ga | 1988 |
Therapeutic regimens in acute experimental hemorrhagic pancreatitis. Effects of hydration, oxygenation, peritoneal lavage, and a potent protease inhibitor.
Topics: Acute Disease; Animals; Female; Fluid Therapy; Gabexate; Guanidines; Mice; Oxygen; Pancreas; Pancrea | 1988 |
Synthetic versus natural protease inhibitors in acute experimental pancreatitis.
Topics: Animals; Esters; Gabexate; Guanidines; Male; Pancreatitis; Plasma; Protease Inhibitors; Rats | 1988 |
[Protective effect of camostat mesilate and allopurinol in acute edematous pancreatitis in the rat induced by excessive doses of caerulein].
Topics: Acute Disease; Allopurinol; Animals; Ceruletide; Edema; Esters; Gabexate; Guanidines; Male; Pancreat | 1987 |
[Phospholipase A2 inhibitors in hemorrhagic-necrotizing pancreatitis. Animal experiment evaluation of a new treatment concept].
Topics: Acute Disease; Animals; Chlorpromazine; Dogs; Edetic Acid; Female; Gabexate; Guanidines; Hemodynamic | 1985 |